Aristada, Asimtufii, Consta, Hafyera, Initio, Maintena, Perseris, Rykindo, Sustenna, Trinza, Uzedy—which are which?
Here are my medication mascots for aripiprazole, risperidone, and paliperidone. Association of a drug with a mascot is a visual mnemonic technique that enables recollection of many associated facts—in this case, whether the long-acting injectable (LAI) antipsychotic an aripiprazole, risperidone or paliperidone product.
This is the same memory technique used in Cafer's Psychopharmacology: Visualize to Memorize 270 Medication Mascots to distinguish the amphetamines from the methylphenidates. Amphetamine products include an amplifier while those representing methylphenidate products include a Scantron sheet ("Write-a-line" on "Math final date").
Here are the 3 principal mascots for risperidone, paliperidone, and aripiprazole. Antipsychotics are generally represented by spooky characters. They're cringeworthy but effective, at least for me.
After memorizing the 3 main mascots, learn the following pictures and you will know whether, e.g., Uzedy, is an aripiprazole, risperidone or paliperidone product.
Risperidone long-acting injectable (LAI) products:
Consta
Rykindo
Perseris
Risvan
Paliperidone palmitate LAI products:
Sustenna
Trinza
Hafyera
Aripiprazole LAI products:
Maintena
Asimtufii
Aristada
Initio
I had trouble with the spelling of Maintena and Sustenna concerning one vs two N's. Is it Maintena or Maintenna? Sustena or Sustenna? The correct spelling for each is 8 letters: MAIN-TENA and SUST-ENNA.
In Cafer's Psychopharmacology: Visualize to Memorize 270 Medication Mascots, the LAI antipsychotic comparison tables are located on the last page of the green-tabbed sections— Green for antipsychotics, because hallucinations and delusions of "little green men" are signs of psychosis.
Risperidone and Paliperidone LAI products
Dose equivalents / conversions between risperidone and paliperidone products
Aripiprazole LAI products
Dose equivalents / conversions between aripiprazole products
The other antipsychotic LAIs
Comments